[go: up one dir, main page]

AR111236A1 - Uso intradialítico de tiosulfato de sodio - Google Patents

Uso intradialítico de tiosulfato de sodio

Info

Publication number
AR111236A1
AR111236A1 ARP180100530A ARP180100530A AR111236A1 AR 111236 A1 AR111236 A1 AR 111236A1 AR P180100530 A ARP180100530 A AR P180100530A AR P180100530 A ARP180100530 A AR P180100530A AR 111236 A1 AR111236 A1 AR 111236A1
Authority
AR
Argentina
Prior art keywords
intradialitical
tiosulfate
sodium
sodium tiosulfate
methods
Prior art date
Application number
ARP180100530A
Other languages
English (en)
Inventor
Craig Sherman
Original Assignee
Hope Medical Entpr Inc Dba Hope Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hope Medical Entpr Inc Dba Hope Pharmaceuticals filed Critical Hope Medical Entpr Inc Dba Hope Pharmaceuticals
Publication of AR111236A1 publication Critical patent/AR111236A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654—Dialysates therefor
    • A61M1/1656—Apparatus for preparing dialysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente se proporcionan métodos para mantener niveles fisiológicos de tiosulfato en un sujeto que se somete a hemodiálisis. En la presente también se proporcionan métodos para administrar tiosulfato de sodio aceptable desde el punto de vista farmacéutico a un sujeto que se somete a hemodiálisis.
ARP180100530A 2017-03-08 2018-03-07 Uso intradialítico de tiosulfato de sodio AR111236A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762468871P 2017-03-08 2017-03-08

Publications (1)

Publication Number Publication Date
AR111236A1 true AR111236A1 (es) 2019-06-19

Family

ID=63446695

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100530A AR111236A1 (es) 2017-03-08 2018-03-07 Uso intradialítico de tiosulfato de sodio

Country Status (14)

Country Link
US (5) US10744156B2 (es)
EP (2) EP3592824B1 (es)
JP (3) JP7416622B2 (es)
KR (4) KR102758644B1 (es)
AR (1) AR111236A1 (es)
AU (2) AU2018231072B2 (es)
CA (1) CA3055107A1 (es)
ES (1) ES2992792T3 (es)
IL (4) IL295119B2 (es)
NZ (1) NZ756704A (es)
PH (1) PH12019501971A1 (es)
TW (3) TWI789378B (es)
WO (1) WO2018165108A1 (es)
ZA (2) ZA202105781B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102758644B1 (ko) 2017-03-08 2025-01-23 호프 메디칼 엔터프라이즈스, 인크, 디비에이, 호프파마수으티칼즈 티오황산 나트륨의 투석 중 용도
CN112805238A (zh) 2018-07-03 2021-05-14 芬内克制药股份有限公司 无水硫代硫酸钠和其调配物
US11850313B2 (en) * 2019-12-20 2023-12-26 The London Health Sciences Centre Research Inc. Method and compositions for protecting tissue
WO2024092228A2 (en) * 2022-10-28 2024-05-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Localized delivery of sodium thiosulfate nanoparticles to mitigate arterial calcification
CN116573782B (zh) * 2023-04-03 2023-11-03 迁安市宏奥工贸有限公司 脱硫废液的处理方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0218900B1 (en) 1985-09-10 1992-01-22 Research Corporation Technologies, Inc. Osmotic agents for peritoneal dialysis
US5108767A (en) * 1991-06-10 1992-04-28 Abbott Laboratories Liquid nutritional product for persons receiving renal dialysis
US6380163B1 (en) 1992-12-22 2002-04-30 Baxter International Inc. Peritoneal dialysis solutions with polypeptides
FI98538C (fi) * 1993-10-20 1997-07-10 Enso Gutzeit Oy Menetelmä natriumhydroksidin valmistamiseksi valkolipeästä
US6306836B1 (en) 1994-01-21 2001-10-23 Baxter International Inc. Peritoneal dialysis solutions containing maltodextrins and amino acids
US6436969B1 (en) 1995-09-12 2002-08-20 Kansas University Medical Center Research Institute Inc. Dialysis solutions and methods
ES2322689T3 (es) * 1999-09-22 2009-06-25 Advanced Renal Technologies Uso de un dializado con elevado contenido de citrato.
CN1443064A (zh) * 2000-04-26 2003-09-17 俄勒冈健康科学大学 施用含硫醇化学保护化合物的方法
JP4882054B2 (ja) * 2000-09-13 2012-02-22 独立行政法人科学技術振興機構 腹膜透析液およびその調製法
CA2537222A1 (en) 2003-07-09 2005-01-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
JP4796493B2 (ja) 2004-06-23 2011-10-19 協和発酵バイオ株式会社 Ｌ−リジン・クエン酸塩結晶
US20070154570A1 (en) 2004-09-29 2007-07-05 Miller Christopher C Use of nitric oxide in the treatment and disinfection of biofilms
US7834065B2 (en) 2005-01-31 2010-11-16 Bmg Incorporated Medical-use two part reactive adhesive and medical-use resin having self-degradation property
US20090304600A1 (en) * 2008-06-09 2009-12-10 Anupkumar Shetty Intradialytic administration of sodium thiosulfate
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
US20120321724A1 (en) 2009-06-15 2012-12-20 Bryan Nathan S Method of Measuring and Monitoring In Vivo Nitrite Levels
PT2451435T (pt) 2009-07-08 2018-01-15 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Composições farmacêuticas que contêm tiossulfato de sódio
AU2013212264B2 (en) 2012-01-23 2017-05-18 Santalis Pharmaceuticals Inc. Sandalwood oil and its uses related to clostridium infections
JP2015516407A (ja) * 2012-05-10 2015-06-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 異所性石灰化の治療のためのチオ硫酸ナトリウム
JP5486069B1 (ja) * 2012-11-05 2014-05-07 旭 酒井 透析装置
US20140350097A1 (en) 2013-05-23 2014-11-27 Medinox,Inc. Treatment of hypotension associated with hemodialysis
US11193942B2 (en) * 2014-12-09 2021-12-07 Anna Villarreal Methods and devices for female health monitoring
KR102758644B1 (ko) 2017-03-08 2025-01-23 호프 메디칼 엔터프라이즈스, 인크, 디비에이, 호프파마수으티칼즈 티오황산 나트륨의 투석 중 용도
EP4406595A3 (en) 2017-03-08 2024-10-30 Hope Medical Enterprises, Inc. d.b.a. Hope Pharmaceuticals Intradialytic use of sodium nitrite

Also Published As

Publication number Publication date
TW202315650A (zh) 2023-04-16
EP3592824B1 (en) 2024-06-12
KR102647836B1 (ko) 2024-03-15
AU2024203603A1 (en) 2024-06-20
US12370212B2 (en) 2025-07-29
EP4403215A3 (en) 2024-10-09
ES2992792T3 (en) 2024-12-18
KR102706439B1 (ko) 2024-09-19
IL295119B2 (en) 2023-10-01
US20240100086A1 (en) 2024-03-28
ZA202209104B (en) 2024-12-18
EP4403215A2 (en) 2024-07-24
PH12019501971A1 (en) 2020-06-15
JP2020510680A (ja) 2020-04-09
IL295119B1 (en) 2023-06-01
IL268883B (en) 2022-09-01
IL302827B1 (en) 2024-06-01
KR20240139090A (ko) 2024-09-20
JP7642878B2 (ja) 2025-03-10
CA3055107A1 (en) 2018-09-13
US20250332194A1 (en) 2025-10-30
JP2025084833A (ja) 2025-06-03
US20180256639A1 (en) 2018-09-13
IL295119A (en) 2022-09-01
US10744156B2 (en) 2020-08-18
TW202517284A (zh) 2025-05-01
EP3592824A1 (en) 2020-01-15
JP7416622B2 (ja) 2024-01-17
KR20190129911A (ko) 2019-11-20
IL302827A (en) 2023-07-01
US20200338120A1 (en) 2020-10-29
KR20240038813A (ko) 2024-03-25
IL268883A (en) 2019-10-31
AU2018231072A1 (en) 2019-09-19
JP2024045164A (ja) 2024-04-02
US11116790B2 (en) 2021-09-14
BR112019018646A2 (pt) 2020-04-07
TWI869743B (zh) 2025-01-11
US20220031735A1 (en) 2022-02-03
ZA202105781B (en) 2023-05-31
TWI789378B (zh) 2023-01-11
US11779596B2 (en) 2023-10-10
AU2018231072B2 (en) 2024-04-04
EP3592824A4 (en) 2020-12-23
IL312724A (en) 2024-07-01
TW201840343A (zh) 2018-11-16
KR20250007674A (ko) 2025-01-14
KR102758644B1 (ko) 2025-01-23
IL302827B2 (en) 2024-10-01
NZ756704A (en) 2022-07-01
WO2018165108A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
AR111236A1 (es) Uso intradialítico de tiosulfato de sodio
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
CR20160069A (es) Compuestos terapéuticamente activos y sus métodos de uso
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MX2014015185A (es) Derivados deuterados de ruxolitinib.
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
JOP20160092B1 (ar) علاج البيتا ثلاسيميا باستخدام مصطبة لجائنية
PE20142363A1 (es) Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
NI201500140A (es) Compuestos y composiciones terapéuticos
MX379297B (es) Compuestos alqueno tetrasustituidos y su uso.
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
ZA202307367B (en) Intradialytic use of sodium nitrite
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
BR112019009029A2 (pt) anticorpos anti-bag3 em combinação com inibidores do ponto de verificação imune para uso terapeutico

Legal Events

Date Code Title Description
FC Refusal